[go: up one dir, main page]

PE20130016A1 - Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen - Google Patents

Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen

Info

Publication number
PE20130016A1
PE20130016A1 PE2012000533A PE2012000533A PE20130016A1 PE 20130016 A1 PE20130016 A1 PE 20130016A1 PE 2012000533 A PE2012000533 A PE 2012000533A PE 2012000533 A PE2012000533 A PE 2012000533A PE 20130016 A1 PE20130016 A1 PE 20130016A1
Authority
PE
Peru
Prior art keywords
propoxi
hexahydrocyclopenta
acetylcholinesterase
benzamide
cis
Prior art date
Application number
PE2012000533A
Other languages
English (en)
Inventor
Caryn Trocme-Thibierge
Aurore Sors
Florence Keime-Guibert
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44351420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20130016A1 publication Critical patent/PE20130016A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE A) HIDROCLORURO DE 4-{3-[CIS-HEXAHIDROCICLOPENTA[c]PIRROL-2(1H)-IL]PROPOXI}BENZAMIDA DE FORMULA (I) EN UNA CANTIDAD DE 2MG, 5MG O 20MG; Y B) UN INHIBIDOR DE LA ACETILCOLINESTERASA TAL COMO HIDROCLORURO DE DONEPEZIL EN UNA CANTIDAD DE 10MG, HIDROGENO TARTRATO DE RIVASTIGMINA O HIDROBROMURO DE GALANTAMINA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE TRASTORNOS COGNITIVOS ASOCIADOS AL ENVEJECIMIENTO CEREBRAL Y A LAS ENFERMEDADES NEURODEGENERATIVAS TAL COMO LA ENFERMEDAD DE ALZHEIMER Y A LA ENFERMEDAD DE PARKINSON
PE2012000533A 2011-05-02 2012-04-23 Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen PE20130016A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1101347A FR2974729B1 (fr) 2011-05-02 2011-05-02 Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
PE20130016A1 true PE20130016A1 (es) 2013-01-26

Family

ID=44351420

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000533A PE20130016A1 (es) 2011-05-02 2012-04-23 Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen

Country Status (29)

Country Link
US (3) US8940785B2 (es)
EP (1) EP2520296A1 (es)
JP (1) JP2012232978A (es)
KR (2) KR101493757B1 (es)
CN (1) CN102764439A (es)
AP (1) AP3104A (es)
AR (1) AR086146A1 (es)
BR (1) BR102012010244A2 (es)
CA (1) CA2775624A1 (es)
CL (1) CL2012001102A1 (es)
CR (1) CR20120192A (es)
CU (1) CU20120064A7 (es)
EA (1) EA020987B1 (es)
EC (1) ECSP12011862A (es)
FR (1) FR2974729B1 (es)
GE (1) GEP20146076B (es)
MA (1) MA34776B1 (es)
MX (1) MX2012005103A (es)
NI (1) NI201200070A (es)
PE (1) PE20130016A1 (es)
PH (1) PH12012000088A1 (es)
RU (1) RU2013153140A (es)
SG (2) SG2014010904A (es)
SV (1) SV2012004203A (es)
TN (1) TN2012000177A1 (es)
TW (1) TW201247200A (es)
UY (1) UY34050A (es)
WO (1) WO2012150412A1 (es)
ZA (1) ZA201203163B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2976285B1 (fr) * 2011-06-08 2013-05-24 Servier Lab Procede de synthese et forme cristalline du chlorhydrate de 4-{3-[cis-hexahydrocypenta[c]pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
CN109640975B (zh) 2016-08-18 2020-10-20 苏文生命科学有限公司 组胺-3受体反向激动剂与乙酰胆碱酯酶抑制剂的组合
US20190336509A1 (en) * 2016-08-18 2019-11-07 Suven Life Sciences Limited Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and nmda receptor antagonist
CN108371660B (zh) * 2017-12-14 2020-03-10 五邑大学 一种四氢环戊二烯并吡咯化合物及其衍生物的用途
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
CN114072945B (zh) * 2019-05-21 2025-10-17 La药研科技公司 用于治疗精神障碍、行为障碍、认知障碍的新型药物组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2005238388B2 (en) * 2004-04-28 2011-08-25 Takeda Pharmaceutical Company Limited Fused quinoline derivative and use thereof
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
TW200845977A (en) * 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
BRPI0818366A2 (pt) * 2007-10-10 2015-04-07 Takeda Pharmaceutical Composto, pró-droga, medicamento, método inibidor de faah, métodos de profilaxia ou tratamento para ansiedade, ou depressão, ou de alívio da dor, e de profilaxia ou tratamento para dor inflamatória ou dor neuropática, e, uso do composto.
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
FR2937251B1 (fr) * 2008-10-16 2011-03-18 Servier Lab Utilisation du 4-{3-°hexahydrocyclopenta°c!pyrrol-2(1h)-yl! propoxy}benzamide pour l'obtention de medicaments destines au traitement des troubles du sommeil
FR2953515B1 (fr) * 2009-12-09 2011-12-23 Servier Lab Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
TW201247200A (en) 2012-12-01
GEP20146076B (en) 2014-04-10
WO2012150412A1 (fr) 2012-11-08
UY34050A (es) 2012-11-30
US20120283244A1 (en) 2012-11-08
ZA201203163B (en) 2013-01-30
EA201200527A1 (ru) 2012-12-28
EA020987B1 (ru) 2015-03-31
KR101493757B1 (ko) 2015-02-16
AP3104A (en) 2015-01-31
KR20140051200A (ko) 2014-04-30
CL2012001102A1 (es) 2014-06-20
AR086146A1 (es) 2013-11-20
US8940785B2 (en) 2015-01-27
NI201200070A (es) 2012-11-09
CA2775624A1 (fr) 2012-11-02
CR20120192A (es) 2012-12-06
CU20120064A7 (es) 2013-12-27
MA34776B1 (fr) 2014-01-02
RU2013153140A (ru) 2015-06-10
NZ599633A (en) 2014-02-28
US20150080379A1 (en) 2015-03-19
CN102764439A (zh) 2012-11-07
ECSP12011862A (es) 2012-07-31
FR2974729A1 (fr) 2012-11-09
BR102012010244A2 (pt) 2013-06-18
FR2974729B1 (fr) 2013-04-19
KR20130130238A (ko) 2013-12-02
JP2012232978A (ja) 2012-11-29
EP2520296A1 (fr) 2012-11-07
SG2014010904A (en) 2014-05-29
SV2012004203A (es) 2012-08-23
MX2012005103A (es) 2013-06-05
TN2012000177A1 (fr) 2013-12-12
AP2012006232A0 (en) 2012-04-30
SG185240A1 (en) 2012-11-29
PH12012000088A1 (en) 2023-12-18
US20150080378A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
PE20130016A1 (es) Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmaceuticas que la contienen
MX2014010625A (es) Inhibidores de la beta-secretasa.
DOP2012000225A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
CL2013003484A1 (es) Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras.
IN2014DN09434A (es)
MX2014003886A (es) Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida.
GB2511685A (en) Muscarinic m1 receptor agonists
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
PH12015500746A1 (en) Benzamides
PH12015501398A1 (en) New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
IN2014MN01756A (es)
TN2015000032A1 (en) Inhibitors of beta-secretase
NZ705813A (en) Treatment of mild and moderate alzheimer’s disease
MD4345B1 (ro) Procedeu de sinteză şi forme cristaline ale hidroclorurii de 4-{3-¢cis-hexahidrociclopenta¢c]pirol-2(1H)-il]propoxi}benzamidă şi a bazei libere, compoziţii farmaceutice care le conţin pentru tratamentul tulburărilor cognitive şi psiho-comportamentale
CL2012003437A1 (es) Asociacion que comprende 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda; composicion farmaceutica; y utilizacion para el tratamiento de trastornos cognitivos asociados al envejecimiento cerebral y a enfermedades neurodegenerativas tal como la enfermedad de alzheimer.
MX2015006807A (es) Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas.
WO2014052398A8 (en) Inhibitors of beta-secretase
IN2012DE00262A (es)
PE20170332A1 (es) NUEVA ASOCIACION ENTRE LA 8-CICLOPROPIL-3-[2-(3-FLUOROFENIL)ETIL]-7,8-DIHIDR0-3H-[1,3]0XAZIN0[6,5-g][1,2,3]BENZOTRIAZINA-4,9-DIONA Y UN INHIBIDOR DE LA ACETILCOLINESTERASA Y LAS COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN
MA37955A1 (fr) Inhibiteurs de bêta-secrétase
GEP20156233B (en) New combination between 4-{3-[cis-hexahydrocyclopenta [c]pyrol-2(1h)-yl]propoxy} benzamide and nmda receptor antagonist and pharmaceutcal compositions containing thereof
WO2012111021A8 (en) Substituted 1, 2, 3, 4-tetrahydroquinolin-7-yl carbamates as acetylcholinesterase inhibitors for treatment of alzheimer's disease

Legal Events

Date Code Title Description
FC Refusal